Renaissance Technologies - INTERCEPT PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
Renaissance Technologies ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$15,310
+57.4%
825,800
-6.1%
0.03%
+85.7%
Q2 2023$9,726
-31.0%
879,400
-16.3%
0.01%
-26.3%
Q1 2023$14,104
+61.0%
1,050,200
+48.3%
0.02%
+58.3%
Q4 2022$8,762
-99.9%
708,300
-4.2%
0.01%
-20.0%
Q3 2022$10,312,000
+89.8%
739,200
+87.9%
0.02%
+150.0%
Q2 2022$5,433,000
+55.2%
393,400
+82.8%
0.01%
+50.0%
Q1 2022$3,501,000
-11.8%
215,200
-11.6%
0.00%
-20.0%
Q4 2021$3,968,000
+33.9%
243,569
+22.0%
0.01%
+25.0%
Q3 2021$2,964,000
+260.6%
199,600
+460.7%
0.00%
+300.0%
Q1 2021$822,000
-92.4%
35,600
-91.9%
0.00%
-91.7%
Q4 2020$10,794,000
+6.4%
437,000
+78.6%
0.01%
+20.0%
Q3 2020$10,145,000
-33.9%
244,700
-23.6%
0.01%
-23.1%
Q2 2020$15,341,000
-20.5%
320,200
+4.5%
0.01%
-31.6%
Q1 2020$19,291,000
+68.8%
306,400
+232.3%
0.02%
+111.1%
Q4 2019$11,425,000
+1751.7%
92,200
+1707.8%
0.01%
+800.0%
Q2 2017$617,000
-94.0%
5,100
-91.7%
0.00%
-95.8%
Q3 2015$10,217,000
-31.1%
61,600
+0.3%
0.02%
-29.4%
Q2 2015$14,821,000
+591.3%
61,400
+844.6%
0.03%
+580.0%
Q1 2014$2,144,0006,5000.01%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders